


## Osprey Medical National Kidney Month Programs

**March 21, 2018- Minnesota, United States and Melbourne, Australia** – Osprey Medical (ASX: OSP) today released highlights of educational programs for Physicians, hospital staff and patients for National Kidney Month in the United States.

The program started at the **National Cardiovascular Data Registry annual meeting** (NCDR) on March 6-9 where Osprey launched its Continuing Medical Education program on Acute Kidney Injury (AKI) for Physicians, Nurses and Technologists. With over 2000 attendees Osprey's booth was busy with NCDR specialists who track their hospitals quality outcomes, such as AKI, looking for solutions to improve patient outcomes. Osprey publicised its continuing education program on Kidney Damage Awareness and leads received for DyeVert Plus evaluations will be serviced by Osprey's field sales force.



The **American College of Cardiology** held its annual Scientific Sessions March 9-12 with over 6,000 heart specialists in attendance. The DyeVert Plus was featured at the Innovation Stage with a podium presentation by Dr Gurm on the importance of dye threshold, monitoring and dye minimization. Following his presentation Dr Gurm was interviewed by Dave Fornell, a leading healthcare journalist and editor of DAIC; this interview is available at <https://www.dicardiology.com/videos/video-how-avoid-acute-kidney-injury-cath-lab>. Osprey had a booth with a DyeVert Plus demonstration model and the traffic was consistent with increased activity following Dr Gurm's presentation. All demonstration participants will be contacted for hospital evaluations of the DyeVert system.

The DyeVert Plus will also be featured at the **Society for Cardiovascular Angiography and Interventions (SCAI)** Scientific Session in April 2018. An abstract entitled, *A Multi-Center Observational Study of the DyeVert Plus™ Contrast Reduction System* was selected as one of the "Best of Best" abstracts for the Scientific Sessions. The abstract will be orally presented with details on the primary outcome, dye volume saved and secondary outcomes of dye-related and device-related adverse events. Osprey will have a booth with the DyeVert Plus demonstration model as well as distribute information on its Kidney Damage Awareness CME program.

The company leveraged National Kidney Month to introduce **new materials for its "Be Kind to Kidneys"** educational campaign. This educational site <http://ospreymed.com/be-kind-to-kidneys> has materials for patients and providers on Acute Kidney Injury – the problem, the impact and the solution. Osprey will also publish a patient video as a part of National Kidney Month featuring a DyeVert Plus patient who needed a heart imaging procedure and where the DyeVert Plus was used to lower her risk of dye related kidney damage.

President and CEO Mike McCormick commented:

*"Osprey continues to build market awareness and adoption which are the keys to our commercialization strategy. We are pleased with the level of physicians, hospital staff and patient interest in our National Kidney Month programs. Osprey continues to expand utilization of DyeVert Plus in existing customers and open new hospitals who are focused on reducing AKI. The fundamentals of our commercial strategy are unchanged and we are pleased with the interest from Physicians wanting to protect their chronic kidney disease patients from the harmful effects of dye."*

--ENDS--

**Contact details:****Media**

Amanda Loh  
Buchan Consulting  
T: (613) 8866 1210  
[aloh@buchanwe.com.au](mailto:aloh@buchanwe.com.au)

**Investors**

Rebecca Wilson  
Buchan Consulting  
M: (61) 417 382 391  
[rwilson@buchanwe.co.au](mailto:rwilson@buchanwe.co.au)

**Company**

Doug Schoenberg  
VP of Marketing  
T: (952) 955 8230  
[dschoenberg@ospreymed.com](mailto:dschoenberg@ospreymed.com)

**About Osprey**

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast Induced Acute Kidney Injury (AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ Plus System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

**Foreign Ownership Restriction**

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.